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Abstract—We present in this paper the first ex vivo implantation 
results of our minimally invasive glaucoma drainage device 
(GDD.)  The GDD is designed to treat glaucoma patients by 
draining out their extraneous aqueous humor out of the anterior 
chamber utilizing a MEMS micro-fluidic normally closed (NC) 
check valve.  The NC check valve is encapsulated in protective 
tubing made from parylene C, which has been proved to be 
biocompatible in implantation.  A new packaging and a bench-
top testing procedure is established to characterize the integrated 
GDD prior to its implantation into enucleated porcine eyes.  Pre-
implanted characterization curve demonstrates a cracking 
pressure of 10-20 mmHg of the NC check valve, which agrees 
with our theoretical design.  Ex vivo implantation results show 
that cracking pressure is measured as 24 mmHg by unloading the 
eye pressure.  The little offset of the cracking pressure comes 
from the differences between the in vitro and ex vivo testing 
environments.  The hysteresis behavior of the NC check valve is 
also examined during implantation and is presented here. 
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I. INTRODUCTION
Glaucoma is a kind of eye disease where aqueous humor 
produced by the ciliary body cannot be drained out normally by 
patients’ eyes themselves.  Without successful eye fluid 
drainage, the liquid will accumulated in the anterior chamber of 
the eye, rising eye pressure.  The elevated pressure will then be 
transmitted onto the retina in the back of the eye ball and 
damage the optic nerve, causing a tunnel view of and may lead 
to total blindness if not treated well.  Current major medication 
for glaucoma includes eye drops which either reduces the eye 
fluid production rate or increase the drainage rate.  However, 
eye drops may accompany several side effects such as blurred 
vision, low blood pressure, and fluctuation in heart rhythm [1].  
In addition, it also comes with compliance issues since some 
patients could be refractory to all medications.  Glaucoma 
drainage device has been developed as an alternative solution 
to treat glaucoma patients who are resistant to normal 
glaucoma medications.  A successful GDD can drain out 
aqueous humor accumulated inside the anterior chamber 
continuously and lower the intraocular pressure (IOP) to within 
10-20 mmHg.  We previously presented a parylene-tube-type 
GDD paradigm incorporating either one NC check valve or 
dual NC with normally open (NO) check valves that regulate 
intraocular pressure (IOP) passively with no power 
consumption [2]-[3].  The biocompatible parylene tube of the 
GDD can be minimal invasively implanted under the 
conjunctiva using a gauge #19 hypodermic needle, as shown in 
Figure 1.   The key component of the GDD is one NC check 
valve which is designed to open at 10-20 mmHg, allowing 
extraneous aqueous humor to flow out of anterior chamber 
when the IOP is higher than the critical pressure.  However, 
due to different environmental conditions in vivo and in vitro, 
successful bench-top results are insufficient to predict the 
GDD’s Ex vivo and in vivo behaviors.  Here we present a study 
of the Ex vivo implantation of the GDD, discussing the 
packaging and testing procedure before the surgery, and also 
the results after the implantation.  An enucleated porcine eye is 
used as our implantation model in the process and a height-
adjustable saline bottle is used to mimic eye fluid and simulate 
different eye pressure situations. 
Figure 1. Concept of subconjunctival implantation of a glaucoma drainage 
device.  The overall implantation is done using hypodermic needle incision. 
Figure 2. Glaucoma drainage device configuration.  It comprises one 
Normally-Closed (NC) check valve, one parylene micro tube and that 
mounted onto a rollable parylene anchor. 
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II. DEVICE DESIGN
A GDD configuration is shown in Figure 2.  It comprises 
three major parts: one NC check valve, one parylene micro 
tube and one rollable parylene anchor. 
A. Design of NC check valve 
The NC check valve remains closed as long as eye pressure 
is lower than the designed cracking pressure.  It restricts eye 
fluid from leaking out of the anterior chamber, which otherwise 
causes hypotony.  Owing to the inherent structure of the NC 
valve, fluid coming from the opposite way will be rejected, 
protecting the anterior chamber from any unwanted fluid 
flowing in.  The cross section of the NC check valve is shown 
in Figure 3.  The necessary pre-stress is introduced by stiction 
adhesion after the drying process, which occurs between 
parylene and silicon surface, and pulls down the tethers.  The 
cracking pressure can be controlled by many parameters such 
as height of the stiction part of the parylene, parylene thickness, 
tether numbers, and the geometry of tethers. The flow rate is 
defined by the size of the opening orifice and the opening gap 
of the parylene membrane.  The proper geometry of check 
valves was designed and simulated by finite element analysis 
software, COSMOS, as shown in Figure 4. Because eye 
pressure is measured as 10-20 mmHg for normal people, 15 
mmHg is picked up as the cracking pressure during its 
simulation.  The outer diameter (OD) of the check valve is 
designed to be 500 µm so that the overall GDD size can be fit 
into gauge #19 needle, which inner diameter (ID) is 690 µm.  
Valve pre-stressed by natural stiction
Figure 3. Cross-section of a Normally-Closed (NC) check valve.  The valve 
is pre-stressed by natural stiction which inevitably happens after drying 
process. 
Figure 4. COSMOS mechanical analysis of normally-cloased check valves 
B. Design of parylene micro tube 
There are 2 main issues of the accommodation tube to 
concern about: the biocompatibility and the size.  In terms of 
the biocompatibility, parylene C (poly para-xylylene C) is used 
as our micro tube material.  Parylene C is classified in FDA’s 
USP class VI and is totally implantable in human bodies.  In 
terms of the size, the OD of the tube cannot be bigger than 690 
µm and ID should be larger than 500 µm.  The length of the 
tube is trimmed to 6mm long to fit in the eye.  Both ends of the 
tube are slanted with 30 degree for easy implantation. 
C. Design of parylene anchor 
The anchor is made of parylene C, with rollable swings that 
are squeezed into hypodermic needle during implantation and 
rolled out afterward.  A trench with 300 µm in radius is 
designed to accommodate the parylene micro tube.  The overall 
length is designed as 5 mm, which is shorter than the tube so 
that the slanted end of the tube can be exposed during 
implantation. 
III. DEVICE FABRICATION
A. Fabrication of NC check valves 
The main fabrication processes are shown in Figure 5.  The 
fabrication started with growing thermal oxide on silicon 
surface.  DRIE was then performed to define the location of 
orifices and the boundary of valves on the back side.  XeF2 was 
used to roughen the front side surface to help parylene 
anchoring.  3-step lithography was done to create 3 different 
photoresist heights.  Parylene was then coated, patterned, and 
the orifices were opened by DRIE on the back side again.  
Photoresist was stripped by soaking in the acetone and the 
whole valve can be released manually when in need. 
B. Fabrication of parylene micro tubes and anchors 
There are two ways to manufacture parylene micro tubes. 
One choice is to coat parylene directly onto both inside and 
outside of commercialized glass tubes.  The other way is to 
coat only on the outer surface.  Although, for the former 
approach, it may be biocompatible by coating a layer of 
parylene on the glass, it still remains very brittle and is highly 
possible to break inside the eye or during the surgery.  
Therefore we chose the latter approach that coats parylene only 
on the outer surface of glass tubes and released the glass inside 
the parylene micro tubes by soaking tubes long in BHF.  The 
thickness of the tube is another concern in terms of 
implantation.  It can neither be too thin nor too thick.  Thinner 
parylene tends to be crashed in the eye due to the muscle 
pressure and thicker parylene becomes difficult to fit in a small 
gauge needle.   
The fabrication of parylene anchors start with XeF2 silicon 
isotropic etching using oxide as the etching mask.  After oxide 
mask removed, the front side silicon surface was coated with a 
layer of parylene and then aluminum.  A layer of dry film 
photoresist was then laminated on top of the trenches and 
patterned, which becomes the mask for aluminum etching.  
Parylene was later patterned using etched aluminum layer and 
the whole parylene anchor can be released by soaking in DI 
water with the help of ultrasonic. 
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1. 2 sides oxidation and patterning, (1st mask)
2. XeF2 isotropic etching
1. Oxide removing
2. Parylene coating
3. Aluminum deposition
4. Dry film photoresist lamination and patterning (2nd mask)
5. Aluminum etching
1. Parylene RIE etching
2. Aluminum stripping
3. Parylene releasing
1. Back side DRIE
2. Photoresist stripping and stiction happens afterwards
1. Two side oxide growing
2. Back side lithography, (1st mask)
3. Back side oxide patterning and DRIE
4. Front side XeF2 surface roughening, (2nd mask)
1. Front side three-steps lithography, (3rd, 4th and 5th masks)
2. Front side parylene coating and patterning, (6th Mask)
Silicon Oxide Parylene Photoresist Aluminum Dry film photoresist
Figure 5. Fabrication process of (left) NC check valves and (right) parylene anchors. 
Figure 6. Pre-implanted preparation procedures: (a) releasing NC check 
valves from a chip; (b) packaging valve within a tube and sealing the valve-
tube with photoresist in another capillary tube; (c) in vitro testing; (d) 
releasing the valve-tube by acetone and IPA and attached onto parylene 
fixation anchors. 
IV. DEVICE PACKAGING AND BENCH-TOP TESTING
The chip with valves was first dipped into acetone, IPA and 
DI water to strip off protective photoresist.  Each valve is 
released from the chip by breaking silicon connection part as 
shown in Figure 6.  The NC check valve was then inserted with 
parylene side facing the interior of the parylene micro tube in 
order to prevent damaging the parylene membrane during 
implantation.  The slit between the valve and the parylene 
micro tube was completely sealed by epoxy.  After epoxy dried, 
the valve-tube assembly was inserted into DuPont Teflon FET 
capillary tube, and photoresist was used to seal the gap between 
FET tube and valve-tube structure.  The FET tube was cut into 
2 inch segments in advance and the integrated valve-tube 
assembly was attached to one end of the capillary tube.  The 
whole setup was baked to dry in a convectional oven at 100 °C.  
After photoresist dried, each assembly was connected to the 
testing setup shown in Figure 6. The bench-top testing setup 
used compressed nitrogen to applied pressure to water.  The 
setup also contains one pressure regulator and one pressure 
gauge.  Water is used as working fluid to mimic the eye fluid.  
The flow rate is calculated by measuring the marching speed of 
the moving water front.  The characteristic curve of every 
assembly was generated and also filmed.  In order to get a 
qualified working device, the result of the cracking pressure is 
required to fall in between 10-20 mmHg.  It’s also required that 
water drips should only be observed flowing out through the 
opening of valve-tubes, not the slit between valve-tubes and the 
FET tubes.  In vitro testing results are shown in TABLE I. 
Tested and qualified valve-tube devices were then released by 
acetone and IPA and attached to a parylene fixation anchor.
TABLE I. IN VITRO AND EX VIVO CRACKING PRESSURE RESULTS:
Measured Cracking Pressure (mmHg) In vitro Ex vivo
GDD 1 17 15-25* 
GDD 2 12 24 
*Number is obtained by estimation from video timeline.
(a)
(b)
(c)
(d)
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Figure 7. Testing setup of ex vivo implantation. 
Figure 8. Ex vivo implantation result of GDD 1. 
Figure 9. Ex vivo implantation results of GDD 2: (a) Dye started to drain out 
after fluids injected and stopped at 24mmHg; (b) Residual dye remained 
slightly flowing at 4mmHg. 
V. EX VIVO IMPLANTATION AND DISCUSSION
A gauge #19 hypodermic needle and a blunt end plunger 
are used as the GDD carrier and deliverer, respectively.  Two 
ex vivo implantations are performed to understand the behavior 
of the integrated GDD implanted in enucleated porcine eyes 
and the function of the parylene fixation anchor.  The ex vivo
implantation setup is shown in Figure 7. , with saline as the 
working fluid.  It can be shown that parylene fixation anchor 
helps the GDD stay firmly without moving successfully after 
needle retracted.  The ex vivo testing results are also 
summarized in TABLE I.  The infusion line was connected to 
the vitreous chamber so that different pressures can be 
provided by raising the infusion bottle.  After implantation, a 
blue dye was injected into the anterior chamber, then the 
infusion bottle was raised up to increase the pressure.  Soon 
after the infusion line was turned on, the dye was seen to come 
out of the GDD, as shown in Figure 8. After a few seconds, 
when the IOP reaches 52mmHg, the infusion line is turned off.  
The video shows that GDD successfully opened to drain out 
the dye well before the IOP reached its final 52 mmHg.  From 
the timeline of the video, the turn-on pressure is around 15-25 
mmHg. 
To understand more about the behavior of the external end 
of the GDD, another implantation was performed with one end 
of the GDD exposed to air.  Unlike the previous setup, the 
infusion line and the dye were both inserted and injected 
directly into anterior chamber to mimic the accumulation of 
aqueous humor during real glaucoma.  Video recordings show 
that once saline and dye were both injected into the anterior 
chamber, the GDD started to drain out the liquid, as shown in 
Figure 9.  We adjusted the saline flow rate and observed that 
the GDD stopped to drain out fluids at 24 mmHg.  The offset 
of the cracking pressure is possibly due to differences between 
in vitro and ex vivo testing environments.  A hysteresis study 
was also executed at the end of the test to quantify the lowest 
pressure required to keep the GDD open. Using a cotton swab, 
capillary forces were introduced to continually pull eye fluids 
out of the GDD.  It was observed that the dye flow continued 
until the pressure reached 4 mmHg IOP for a few seconds. This 
result indicates that the response time of the valve’s restoring 
force could be as long as several seconds.  After 
experimentation, the implanted GDD was retracted and 
investigated.  More detailed hysteresis behavior study is also 
underway. 
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